BRCA mutation testing in determining breast cancer therapy

Cancer Journal

Volumn 17, Issue 6, 2011, Pages 492-499

  Smith, Karen Lisa ^a   Isaacs, Claudine ^b  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

BRCA1; BRCA2; breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE;

AMENORRHEA; BONE MARROW SUPPRESSION; BRCA GENE; BRCA2 GENE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; GENETIC COUNSELING; HUMAN; MASTECTOMY; MEDICAL DECISION MAKING; ONCOGENE; OVARIECTOMY; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; TREATMENT RESPONSE;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS;

EID: 83755228983     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318238f579     Document Type: Review

References (80)

1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329-1333. (Pubitemid 46706879)
2. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324. (Pubitemid 26162426)
3. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96:222-226. (Pubitemid 39612440)
4. Liebens FP, Carly B, Pastijn A, et al. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer. 2007;43:238-257.
5. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat. 2010; 119:13-24.
6. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26:4282-4288.
7. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43:867-876. (Pubitemid 46366688)
8. James CR, Quinn JE, Mullan PB, et al. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist. 2007;12:142-150.
9. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28:2512-2519.
10. Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer. [published online ahead of print June 29, 2011] doi:10.1002/cncr.26294.
11. Evans DG, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev. 2009;18: 2318-2324.
12. Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823-1829. (Pubitemid 41095172)
13. Weitzel JN, McCaffrey SM, Nedelcu R, et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. 2003;138:1323-1328; discussion 1329.
14. Doll KM,Weldon CB, Trosman JR, et al. BRCA+ test result impact and timing on surgical treatment decisions for patients with breast cancer. J Clin Oncol. 2011;29(suppl). Abstract 626.
15. Trosman JR, Weldon CB, Gradishar WJ, et al. Timing of genetic testing relative to breast cancer surgery. J Clin Oncol. 2010;28(suppl):15s. Abstract 666.
16. D'Souza A, Dohany L, Ducaine W, et al. Impact of BRCA 1 and 2 gene mutation testing on surgical decision-making in newly diagnosed breast cancer patients. Cancer Res. 2010;70(suppl 2). Abstract P2-10-03.
17. Cortesi L, De Matteis E, Razzaboni E, et al. Effect of rapid genetic testings on the rate of bilateral prophylactic mastectomy in BRCA1/2 mutation carriers. J Clin Oncol. 2011;29(suppl). Abstract 1511.
18. Tercyak KP, Peshkin BN, Brogan BM, et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol. 2007;25:285-291. (Pubitemid 350003016)
19. NCCN Guidelines version 1.2011VGenetic/Familial High-Risk Assessment: Breast and Ovarian. Available at: www.nccn.org. Accessed August 13, 2011.
20. Schwartz MD, Lerman C, Brogan B, et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14:1003-1007. (Pubitemid 40478572)
21. Wevers MR, Ausems MG, Verhoef S, et al. Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer. 2011;11:6.
22. King LE, Vegella P, Peshkin BN, et al. Predictors of BRCA1/2 testing in newly diagnosed breast cancer patients. In: Society of Behavioral Medicine 32nd Annual Meeting. Washington, DC: 2011:B-034d.
23. Kirova YM, Savignoni A, Sigal-Zafrani B, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2010;120:119-126.
24. Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2- associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437-2443. (Pubitemid 46630619)
25. Robson M, Levin D, Federici M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999;91:2112-2117. (Pubitemid 30019573)
26. Metcalfe K, Lynch HT, Ghadirian P, et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011;127:287-296.
27. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010; 121:389-398.
28. Robson M, Svahn T, McCormick B, et al. Appropriateness of breastconserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer. 2005; 103:44-51. (Pubitemid 39665455)
29. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27: 5887-5892.
30. Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28: 2404-2410.
31. Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359: 1471-1477. (Pubitemid 34457765)
32. Reding KW, Bernstein JL, Langholz BM, et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat. 2010;123:491-498.
33. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a casecontrol study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356:1876-1881.
34. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22: 2328-2335. (Pubitemid 41115389)
35. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118:2281-2284.
36. Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004;6:R8-R17.
37. Van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005; 93:287-292. (Pubitemid 43080030)
38. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-975.
39. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055-1062. (Pubitemid 41095038)
40. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633-1637. (Pubitemid 33094870)
41. Meijers-Heijboer H, Van Geel B, Van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159-164. (Pubitemid 32662123)
42. Heemskerk-Gerritsen BAM, Hooning MJ, Jager A, et al. Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival? Eur J Cancer Suppl. 2010;8:206.
43. Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26:1093-1097.
44. Graves KD, Peshkin BN, Halbert CH, et al. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat. 2007;104:321-329. (Pubitemid 47231279)
45. Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23: 7849-7856. (Pubitemid 46657383)
46. Geiger AM, Nekhlyudov L, Herrinton LJ, et al. Quality of life after bilateral prophylactic mastectomy. Ann Surg Oncol. 2007;14:686-694. (Pubitemid 46175315)
47. Montgomery LL, Tran KN, Heelan MC, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol. 1999;6: 546-552. (Pubitemid 29428793)
48. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115:359-363.
49. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375-379.
50. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28: 1145-1153.
51. Wen J, Li R, Lu Y, et al. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptorYcoregulator interactions. Oncogene. 2009;28:575-586.
52. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361:123-134.
53. Iglehart JD, Silver DP. Synthetic lethalityVa new direction in cancerY drug development. N Engl J Med. 2009;361:189-191.
54. Carey LA, Sharpless NE. PARP and cancerVif it's broke, don't fix it. N Engl J Med. 2011;364:277-279.
55. Gartner EM, Burger AM, Lorusso PM. Poly(ADP-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer J. 2010; 16:83-90.
56. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357:115-123. (Pubitemid 47057729)
57. Marcus JN, Watson P, Page DL, et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat. 1997;44:275-277. (Pubitemid 27296388)
58. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol. 2006;17:391-400. (Pubitemid 43329574)
59. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96: 1659-1668. (Pubitemid 39585635)
60. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88:1285-1291. (Pubitemid 36606348)
61. Chabalier C, Lamare C, Racca C, et al. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006;5:1001-1007.
62. Arun B, Bayraktar S, Liu DD, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single institution experience. J Clin Oncol. 2011;29:3739-3746.
63. Kriege M, Jager A, Hooning MJ, et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer. [published online ahead of print July 14, 2011] doi:10.1002/cncr.26351.
64. Byrski T, Foszczynska-Kloda M, Huzarski T, et al. Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer. J Clin Oncol. 2009;27: Abstract 1099.
65. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913-917. (Pubitemid 40559005)
66. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921. (Pubitemid 40559006)
67. Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008;14:3916-3925.
68. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105:17079-17084.
69. Drew Y, Mulligan EA, Vong WT, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103:334-346.
70. Hay T, Jenkins H, Sansom OJ, et al. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res. 2005;65: 10145-10148. (Pubitemid 41743700)
71. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126-2132. (Pubitemid 46514749)
72. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376: 235-244.
73. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011; 364:205-214.
74. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin in metastatic triple-negative breast cancer. J Clin Oncol. 2011;29: Abstract 1007.
75. NCCN Guidelines Version 2.2011: Breast Cancer. Available at: www.nccn.org. Accessed August 13, 2011.
76. Wesoloski R, Shealy AG, Tao J, et al. Differential outcomes in patients treated with endocrine therapy for early or locally advanced breast cancer based on BRCA mutation status. J ClinOncol. 2009;27: Abstract e22065.
77. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
78. Price KN, Goldhirsch A. Clinical trial update: International Breast Cancer Study Group. Breast Cancer Res. 2005;7:252-254. (Pubitemid 41830162)
79. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingooophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331-1337.
80. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80-87.